Database

Startups

Main Industry
Biotechnology
Main Product/Service
1. Heparin API
2. Water Essence – GAGs product
Founded Year
2011
Unified Business No.
53488536
Status
Active
Number of Employees
10
Total Paid-in Capital
255,011,330 (NT$)
Location of Company
Taiwan , Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
About the Company
Bionovax Corp was founded in 2014. Our plant is located in Longtan of Hsinchu Science Park of Taiwan. Company goal is to produce reliable high-quality anti-coagulation drug of heparin (UFH), along with its low-molecular-weight heparin (LMWH) and their applications, which go beyond the anti-coagulation drugs to produce products that can be used in cosmetics and medical devices.



more ↓

Similar Companies

TAHO PHARMACEUTICALS LTD.

1. TAH4411 Ondansetron ODF
2. TAH3311 Apixaban Oral Film
3. TAH3341 Apixaban Oral Extend Release Film
4. TAH2211 Buprenorphine/Naloxone Sublingual Film
5. TAH2231 Naloxone Buccal Film
6. TAH9922 Atomoxetine Oral Liquid
7. TAH9901 Methylphenidate Patch

PET PHARM BIOTECH CO., LTD.

1. Fluorodeoxyglucose injection(¹⁸F-FDG)
2. ¹⁸F-NaF
3. ¹⁸F-NaF
4. 131I capsule

Taiwan Universe BioMedicine Inc.

Main Product
Innovative platform of enterovirus and influenza VLP vaccines
Promising option to combat viruses mutation
Provide a broad-spectrum prevention with better immunogenicity
Enable faster scaling-up

ImmunAdd Inc.

ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immun
:::
回頁面最頂端